Drugs, money, and secret handshakes : the unstoppable growth of prescription drug prices
Record details
- ISBN: 9781108482455
- ISBN: 1108482457
- ISBN: 9781108687676
-
Physical Description:
print
xiv, 186 pages ; 24 cm - Publisher: Cambridge, United Kingdom ; New York, NY, USA Cambridge University Press, 2019.
- Copyright: ©2019
Content descriptions
Bibliography, etc. Note: | Includes bibliographical references and index. |
Formatted Contents Note: | 1. Introduction; 2. The landscape -- where do the dollars flow; 3. Pharmacy Benefit Managers (PBMs) and insurers; 4. Pharmacies, doctors, and patient groups; 5. May your drug price be ever green; 6. Solutions. |
Search for related items by subject
Subject: | Pharmaceutical industry Economic aspects Drugs Cost effectiveness Pharmaceutical policy Drug Costs Drug Industry economics Pharmaceutical Preparations economics Drug and Narcotic Control |
Available copies
- 1 of 1 copy available at Kirtland Community College.
Holds
- 0 current holds with 1 total copy.
Show Only Available Copies
Location | Call Number / Copy Notes | Barcode | Shelving Location | Status | Due Date |
---|---|---|---|---|---|
Kirtland Community College Library | RS 100 .F45 2019 | 30775305544760 | General Collection | Available | - |
Drugs, Money, and Secret Handshakes : The Unstoppable Growth of Prescription Drug Prices
Click an element below to view details:
Summary
Drugs, Money, and Secret Handshakes : The Unstoppable Growth of Prescription Drug Prices
In the warped world of prescription drug pricing, generic drugs can cost more than branded ones, old drugs can be relaunched at astronomical prices, and low-cost options are shut out of the market. In Drugs, Money and Secret Handshakes, Robin Feldman shines a light into the dark corners of the pharmaceutical industry to expose a web of shadowy deals in which higher-priced drugs receive favorable treatment and patients are channeled toward the most expensive medicines. At the center of this web are the highly secretive middle players who establish coverage levels for patients and negotiate with drug companies. By offering lucrative payments to these middle players (as well as to doctors and hospitals), drug companies ensure that inexpensive drugs never gain traction. This system of perverse incentives has delivered the kind of exorbitant drug prices - and profits - that everyone loves except for those who pay the bills.